Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

研究成果: ジャーナルへの寄稿評論記事

1 引用 (Scopus)

抄録

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

元の言語英語
ページ(範囲)267-276
ページ数10
ジャーナルExpert Review of Anticancer Therapy
18
発行部数3
DOI
出版物ステータス出版済み - 3 4 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
Patient Selection
Drug Resistance
Radiotherapy
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

これを引用

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer. / Iwama, Eiji; Nakanishi, Yoichi; Okamoto, Isamu.

:: Expert Review of Anticancer Therapy, 巻 18, 番号 3, 04.03.2018, p. 267-276.

研究成果: ジャーナルへの寄稿評論記事

@article{6b72f2f2aca54da9838507a64051f6fe,
title = "Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer",
abstract = "Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.",
author = "Eiji Iwama and Yoichi Nakanishi and Isamu Okamoto",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/14737140.2018.1432356",
language = "English",
volume = "18",
pages = "267--276",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

AU - Iwama, Eiji

AU - Nakanishi, Yoichi

AU - Okamoto, Isamu

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

AB - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

UR - http://www.scopus.com/inward/record.url?scp=85042351253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042351253&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1432356

DO - 10.1080/14737140.2018.1432356

M3 - Review article

VL - 18

SP - 267

EP - 276

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -